Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia
Alzheimer's & Dementia · 2025-04 · 21 (4)
DOI: 10.1002/alz.14423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 12.04.2025. Verfasst von Roos M Rikken und 17 weiteren Autor:innen. Beteiligte Einrichtung: Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, tau Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer Nederland, EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION A subset of amyloid beta (Aβ)‐positive Alzheimer's disease (AD) patients is tau‐positron emission tomography (PET) negative. We aimed to characterize this subgroup using [ 18 F]flortaucipir PET visual read (VR), as this is important for prognosis and selection for therapies. METHODS Aβ‐positive VR tau‐PET‐negative AD dementia patients (AD A+T−) were compared to tau‐PET‐positive AD patients (AD A+T+) and control groups (CU A−T−; CU A+T−) included from the Amsterdam‐based cohort and Alzheimer's Disease Neuroimaging Initiative (ADNI). We compared [ 18 F]flortaucipir binding in an early‐ and late‐stage tau ROI, atrophy, cognition, and co‐pathologies. RESULTS AD A+T− were older, showed less hippocampal atrophy and slower cognitive decline compared to AD A+T+. In ADNI, AD A+T− showed higher early‐stage tau binding compared to both control groups and more late‐stage tau compared to CU A−T−, but no tau accumulation over time. DISCUSSION VR tau‐PET‐negative AD patients show neurodegenerative and cognitive processes consistent with the AD trajectory, but milder progression compared to tau‐PET‐positive AD patients. Highlights We used the novel Food and Drug Administration (FDA)‐approved VR method for defining tau‐PET positivity. AD A+T− patients were older and showed less atrophy and cognitive decline than AD A+T+. We did not find convincing evidence of tau accumulation in AD A+T− or copathologies. The group of AD A+T− patients is likely very heterogeneous.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
- Amsterdam Neuroscience, Brain Imaging, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
- Biological Psychiatry, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Clinical Memory Research Unit, Clinical Sciences Malmö, Faculty of Medicine, Lund University, Skånes Universitetssjukhus, VE Minnessjukdomar, Malmö, Sweden.
ORCID-Profile: Roos M Rikken
Förderung
- Alzheimer Nederland
- EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking
- NIA NIH HHS
- ZonMw
- Janssen Pharmaceuticals
- ZonMw Memorabel grant
- The Alzheimer's Disease Neuroimaging Initiative (ADNI)
- European Union's Horizon 2020 research and innovation program
Zitieren
APA
Rikken, R. M., Coomans, E. M., de Koning, L. A., Visser, D., Neutelings, E., den Braber, A., Collij, L. E., Golla, S. S. V., Alzheimer's Disease Neuroimaging Initiative, Barkhof, F., Visser, P. J., Scheltens, P., van der Flier, W. M., Boellaard, R., Ossenkoppele, R., Vijverberg, E. G. B., van de Giessen, E., & for ADNI (2025). Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia. Alzheimer's & Dementia, 21(4). https://doi.org/10.1002/alz.14423
Vancouver
Rikken RM, Coomans EM, de Koning LA, Visser D, Neutelings E, den Braber A, et al. Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia. Alzheimer's & Dementia. 2025;21(4). doi:10.1002/alz.14423
BibTeX
@article{Rikken2025,
author = {Rikken, Roos M and Coomans, Emma M and de Koning, Lotte A and Visser, Denise and Neutelings, Eline and den Braber, Anouk and Collij, Lyduine E and Golla, Sandeep S V and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Barkhof, Frederik and Visser, Pieter Jelle and Scheltens, Philip and van der Flier, Wiesje M and Boellaard, Ronald and Ossenkoppele, Rik and Vijverberg, Everard G B and van de Giessen, Elsmarieke and for ADNI, for ADNI},
title = {Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {4},
doi = {10.1002/alz.14423}
}
EUVIMED